tirzepatide class of drug (Zepbound) – A New Treatment for Obstructive Sleep Apnea and Obesity — BetterNight Tirzepatide | C225H348N48O68 | CID

instead, work with their provider to adjust dose, rate of weight loss, and nutritional support

Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland When using this product do not exceed recommended dose Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with a fever If pregnant or breast-feeding , ask a health professional before use

However, in an analysis of the same trial, early responders (those who lost more than 10% by week 16) have shown an average weight loss of 22% after 64 weeks

Hematol Am Soc Hematol Educ Program 2014:432437 Centers for Disease Control and Prevention (CDC)